Aramchol

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fatty Liver

Conditions

Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses

Trial Timeline

Apr 29, 2015 → May 22, 2018

NCT ID

NCT02279524

About Aramchol

Aramchol is a phase 2 stage product being developed by Galmed Pharmaceuticals for Fatty Liver. The current trial status is completed. This product is registered under clinical trial identifier NCT02279524. Target conditions include Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases.

What happened to similar drugs?

6 of 12 similar drugs in Fatty Liver were approved

Approved (6) Terminated (3) Active (4)

🔄GODEX + PlaceboCelltrionPhase 3

✅Orlistat (Xenical)RocheApproved

✅Xenical, Pegasys, CopegusRocheApproved

✅atorvastatin + Vitamin EPfizerApproved

❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3

✅Testosterone Undecanoate + PlaceboBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07251712	Phase 1	Recruiting	Dec 25, 2025	May 15, 2026	Healthy
NCT05874336	Phase 1	Completed	Jun 17, 2020	Aug 11, 2020	NASH
NCT03774173	Phase 1	Completed	Dec 8, 2018	Mar 5, 2019	Healthy
NCT02279524	Phase 2	Completed	Apr 29, 2015	May 22, 2018	Fatty Liver

Competing Products

20 competing products in Fatty Liver

See all competitors

Product	Company	Stage	Hype Score
Lanifibranor	Inventiva	Phase 2	29
Low Dose REN001 + High Dose REN001	OnKure Therapeutics	Phase 1	19
GODEX + Placebo	Celltrion	Phase 3	47
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo	AstraZeneca	Phase 2	35
AZ compound	AstraZeneca	Phase 2	27
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo	AstraZeneca	Phase 2	35
AZD7503 Intervention	AstraZeneca	Phase 1	29
metformin	Merck	Phase 2/3	34
Efinopegdutide + Semaglutide + Placebo	Merck	Phase 2	35
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride	Merck	Phase 1	29
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL	Merck	Phase 2	35
LYS006 + Tropifexor	Novartis	Phase 2	27
LJN452	Novartis	Phase 1	29
LCQ908 + placebo	Novartis	Phase 2	35
Orlistat (Xenical)	Roche	Approved	43
Xenical, Pegasys, Copegus	Roche	Approved	43
Placebo + RO5093151	Roche	Phase 1	29
AMG 609 + Placebo	Amgen	Phase 1	29
Glucagon	Novo Nordisk	Pre-clinical	26
Blood samples	Novo Nordisk	Pre-clinical	18